Tirzepatide Brand Name: Mounjaro vs. Zepbound Explained

Last reviewed: May 17, 2026

Last updated: May 17, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Tirzepatide is marketed under two brand names: Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management). Both contain identical active pharmaceutical ingredient but carry different FDA indications, dosing protocols, and regulatory pathways. This distinction matters for insurance coverage, prescribing context, and clinical outcomes.

Whether you're exploring branded tirzepatide or compounded alternatives, understanding these distinctions supports clearer conversations with your healthcare provider about which formulation aligns with your health goals, genetics, and treatment history. PlexusDx emphasizes precision-guided decisions backed by biomarker context and individual medication predispositions.

Mounjaro vs. Zepbound: FDA Indication and Clinical Purpose

Mounjaro received FDA approval in 2022 for type 2 diabetes management, with a starting dose of 2.5 mg once weekly. Zepbound, approved in 2023, targets chronic weight management in adults with obesity or overweight with comorbidities, using identical tirzepatide but under a separate indication pathway and marketing authorization.

The clinical distinction reflects regulatory classification, not pharmacological difference. Both formulations activate GLP-1 and GIP receptors. However, diabetes-focused trials emphasize glycemic control, while weight-management studies prioritize percentage body weight loss—typically 15–22% at maintenance doses in clinical populations.

Tirzepatide Formulations: Branded, Compounded, and Dosing Structures

Three main tirzepatide pathways exist: branded Mounjaro (diabetes), branded Zepbound (weight management), and compounded tirzepatide formulations prepared by licensed 503A compounding pharmacies. Compounded versions offer flexible dosing, cost alternatives, and potential accessibility advantages while maintaining pharmaceutical-grade standards.

Formulation Type	Primary Indication	Dosing Range	Typical Cost Range	Source/Availability
Branded Mounjaro	Type 2 diabetes	2.5–15 mg/week	$900–$1,300/month	Pharmaceutical manufacturer; insurance-dependent
Branded Zepbound	Chronic weight management	2.5–15 mg/week	$1,100–$1,400/month	Pharmaceutical manufacturer; insurance coverage varies
Compounded Tirzepatide Injection	Off-label flexibility	Customizable per provider	$249/mo	Licensed 503A pharmacies; typically more accessible
Oral Tirzepatide (Compounded)	Provider-directed dosing	Varies by formulation	$279/mo	503A compounding; emerging option with variable bioavailability

Mechanism of Action: Why Both Brand Names Use the Same Drug

Tirzepatide is a dual GLP-1/GIP receptor agonist. It stimulates insulin secretion, reduces glucagon, slows gastric emptying, and modulates appetite signaling through central nervous system pathways. Clinical trials show consistent metabolic improvements across both indication cohorts, though glycemic endpoints dominate diabetes research.

The dual-receptor mechanism explains why tirzepatide outperforms single GLP-1 agonists in side-by-side comparisons. Studies show tirzepatide 15 mg achieves greater HbA1c reduction and weight loss than semaglutide 2.4 mg in both populations, making brand distinction primarily a regulatory and insurance matter rather than pharmacological one.

Access, Cost, and Clinical Considerations for Brand and Compounded Choices

Branded tirzepatide often requires insurance authorization, prior authorization, or step-therapy protocols. Compounded tirzepatide through licensed 503A pharmacies typically bypasses these barriers and offers lower out-of-pocket costs, though compounded medications are not FDA-approved and should only be prescribed by qualified healthcare providers based on individual clinical assessment.

Patient factors—including genetic predisposition to GIP/GLP-1 responsiveness, comorbid conditions, prior medication history, and insurance coverage—should guide the conversation between patient and provider. Some individuals benefit from genetic testing to understand their peptide pathway predispositions and inform treatment planning with evidence-based precision.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context for tirzepatide response by revealing predispositions in key peptide genetic pathways, including GLP1R rs6923761 and GIPR rs1800437 variants. These biomarkers do not predict exact medication response but can support a more personalized conversation with your healthcare provider about whether tirzepatide aligns with your genetic profile.

Understanding your genetic predispositions in GLP-1 and GIP receptor signaling, combined with clinical biomarkers like fasting glucose, HbA1c, and body composition, may help contextualize which tirzepatide formulation (branded Mounjaro, branded Zepbound, or compounded tirzepatide) could be most appropriate for your individual health goals. The genetic test itself does not replace medical evaluation.

If you're considering tirzepatide—whether branded or compounded—discussing your genetic peptide pathway profile with a qualified provider can inform dosing strategy, formulation choice, and realistic outcome expectations. PlexusDx compounded tirzepatide injections and oral formulations offer cost-effective access while maintaining pharmaceutical-grade quality standards through licensed 503A pharmacies.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is Mounjaro the same as Zepbound?

Both contain identical tirzepatide but differ in FDA indication: Mounjaro targets type 2 diabetes, Zepbound targets chronic weight management. Pharmacologically equivalent; regulatory and insurance distinctions drive the naming difference.

Why do tirzepatide brand names matter for my treatment?

Brand indication affects insurance coverage, dosing recommendations, and prescriber rationale. Understanding which pathway applies to your diagnosis and clinical goals clarifies treatment planning and realistic outcome expectations with your provider.

What is PlexusDx compounded tirzepatide and how does it differ from branded versions?

PlexusDx offers compounded tirzepatide injection ($249/mo) and oral formulations ($279/mo) prepared by licensed 503A pharmacies. Compounded versions provide cost-effective access and flexible dosing but are not FDA-approved; your provider must determine medical appropriateness.

Are there safety differences between Mounjaro and Zepbound?

Safety profiles are equivalent because both formulations contain identical tirzepatide. Reported side effects include nausea, vomiting, and gastrointestinal symptoms, typically dose-dependent and manageable with dose titration under medical supervision.

How can genetic testing help me decide between tirzepatide brands or compounded options?

PlexusDx Precision Peptide Genetic Test reveals predispositions in GLP1R and GIPR pathways, which may provide context for tirzepatide responsiveness. This information, interpreted with your provider, can inform formulation choice and dosing strategy aligned with your individual genetic profile.

Tirzepatide Brand Name: Understanding Mounjaro, Zepbound, and Compounded Options